Company Overview of Sygnis Pharma AG, Prior to Reverse Merger with X-Pol Biotech S.L.
As of December 6, 2012, Sygnis Pharma AG was acquired by X-Pol Biotech S.L., in a reverse merger transaction. SYGNIS Pharma AG, a specialty pharmaceutical company, focuses on the research and development of therapies for the treatment of central nervous system disorders. Its products under development include AX200, a biological molecule, which is in Phase II clinical trials for the treatment of acute ischemic stroke; and KIBRA, which is in pre-clinical stage for the treatment of various forms of dementia. The company was formerly known as LION bioscience AG and changed its name to SYGNIS Pharma AG in January 2007. SYGNIS Pharma AG was founded in 1997 and is based in Heidelberg, Germany.
Im Neuenheimer Feld 515
Founded in 1997
49 6221 454 6
49 6221 454 700
Key Executives for Sygnis Pharma AG, Prior to Reverse Merger with X-Pol Biotech S.L.
Sygnis Pharma AG, Prior to Reverse Merger with X-Pol Biotech S.L. does not have any Key Executives recorded.
Sygnis Pharma AG, Prior to Reverse Merger with X-Pol Biotech S.L. Key Developments
Similar Private Companies By Industry
|BioTissue Technologies GmbH||Europe|
|AB Enzymes GmbH||Europe|
|Pro-tec Medizinische Produkte GmbH||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Sygnis Pharma AG, Prior to Reverse Merger with X-Pol Biotech S.L., please visit www.sygnis.de. Company data is provided by Capital IQ. Please use this form to report any data issues.